We have identified biomarker signatures for MoA, clinical response and toxicity prediction in industry partnerships
Indication | Clinical question | Technology | Tissue | #patients | Outcome and Status |
---|---|---|---|---|---|
Solid tumors (tg T cells) | Prediction of therapy response | scRNA-seq | Infusion cell product | 14 | completedDiscovery project |
Refractory rheumatoid arthritis | Treatment mode of action | scRNA-seq | Murine hind-limbs | 20 | completed Discovery project |
Solid tumors (TIL therapy) | Prediction of therapy response and toxicity | CITEseq, TCRseq | Infusion cell product, PBMCs | 55 | ongoing Discovery project |
Solid tumors (cancer vaccine) | Prediction of therapy response and toxicity | FC, IHC, proteomics, etc. | PBMCs, serum, tumor | 20 | ongoing Discovery project |